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SHP-2 is a tyrosine phosphatase which functions as a positive regulator downstream of RTKs, activating growth-stimulatory signalling
pathways. To date, very few G protein-coupled receptors (GPCRs) have been shown to be connected to SHP-2 and very little is known about the
positive role of SHP-2 in GPCR signalling. The CCK2 receptor (CCK2R), a GPCR, is now recognized to mediate mitogenic effects of gastrin on
gastrointestinal cells. In the present study, we demonstrate the role of SHP-2 in the activation of the AKT pathway by the CCK2R in COS-7 cells
transfected with the CCK2R and in a pancreatic cancer cell line expressing the endogenous receptor. Using surface plasmon resonance analysis,
we identified a highly conserved ITIM motif, containing the tyrosine residue 438, located in the C-terminal intracellular tail of the CCK2R which
directly interacts with the SHP-2 SH2 domains. The interaction was confirmed by pull down assays and co-immunoprecipitation of the receptor
with SHP-2. This interaction was transiently increased following gastrin stimulation of the CCK2R and correlated with the tyrosine
phosphorylation of SHP-2. Mutational analysis of the key ITIM residue 438 confirmed that the CCK2R ITIM sequence is required for interaction
with SHP-2 and the activation of the AKT pathway.
© 2006 Elsevier B.V. All rights reserved.Keywords: Gastrin; CCK2 receptor; G protein-coupled receptor; Cell signalling; Protein interaction1. Introduction
SHP-2 is a widely expressed non-receptor protein tyrosine
phosphatase which functions as a positive regulator down-
stream of Receptor Tyrosine Kinases (RTKs) such as Insulin-
like growth factor-1 (IGF-1) receptor, platelet-derived growth
factor (PDGF) receptor and epidermal growth factor (EGF)
receptor (for review [1]). In addition, SHP-2 plays an important
role in RTK-induced oncogenic cell transformation and cancer
progression. In particular, the transforming capacity of FGFR3,
RETor ERB2 seems to depend on SHP-2 [2]. At present, SHP-2
is the only protein tyrosine phosphatase with a proven
oncogenic function. SHP-2 contains two tandem SH2 domains
at the N-terminus and one tyrosine phosphatase domain at the⁎ Corresponding author. Tel.: +33 5 61322408; fax: +33 5 61322403.
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doi:10.1016/j.bbamcr.2006.07.003C-terminus. In its inactive conformation, the N-terminal SH2
domain of SHP-2 blocks access to the catalytic site of the
molecule. When the SH2 domains interact with a tyrosine
phosphorylated partner protein, the phosphatase is activated [3].
Both the SH2 domains and the phosphatase activity play an
important role in mediating the effects of SHP-2. SHP-2 is
known to directly interact through its SH2 domains with the
phosphorylated tyrosine residues of certain RTKs (PDGF,
EGF). However, it can also bind adaptor proteins such as Grb2,
IRS-1 or Gab which are tyrosine phosphorylated by RTKs [1,2].
It is well known that SHP-2 SH2 domains bind “immuno-
receptor tyrosine-based inhibitory motifs” (ITIM): (I/V/L)xY(p)
xx(I/V/L) (x=any amino acid), initially characterized in
hematopoietic receptors [1]. However, recent publications
have shown that SHP-2 SH2 domains also bind other tyrosine
phosphorylated motifs that belong to the consensus sequence
(T/V/I/Y)xY(p)(A/S/T/V)x(I/V/L) [4,5].
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tyrosine residues within the C-terminal tail in response to growth
factors. Besides a possible adapter role for SH2 containing
proteins, tyrosine phosphorylation of SHP-2 may contribute
directly to positively regulate its phosphatase activity [3].
SHP-2 has been implicated in diverse signaling pathways
initiated by RTK. In particular, SHP-2 is required for the
activation the Ras-ERK cascade, other signalling pathways
involving AKT, and Signal Transducers and Activators of
transcription (STATs) [2] which are involved in cell prolifera-
tion, migration and transformation processes.
To date, very few G protein-coupled receptors (GPCRs) have
been shown to be connected to SHP-2 [6–9] and very little is
known about the positive role of SHP-2 in GPCR signalling.
The CCK2 receptor (CCK2R) is a seven-helix membrane-
spanning receptor principally coupled to Gq proteins [10].
Initially, this receptor was implicated in the secretory effects of a
digestive peptide hormone, gastrin. However, the CCK2R is
now known to mediate the mitogenic and anti-apoptotic effects
of gastrin on gastrointestinal and pancreatic cells [11].
Many of the intracellular signals mediated by the CCK2R are
similar to those activated by RTKs. In particular we and others
have previously reported the activation of the ERK cascade
[12,13], the PI3-kinase/AKT pathway [14,15] and the JAK2/Fig. 1. ITIM-like motifs in the CCK2 receptor sequence. (A) Schematic representation
sequences used to design the biotinylated ITIM peptides (in gray). (B) ComparisonSTAT3 pathway [10] by this GPCR, as well as the involvement
of these signalling molecules in the mitogenic and anti-
apoptotic effects of gastrin.
The tyrosine residue Y438 within the human CCK2R
sequence (Fig. 1A) is a highly conserved ITIM motif (LSY438
TTI) (Fig. 1B) whereas the sequence containing the tyrosine
residue Y390 differs in one amino acid (LVY390CFM). These
two motifs might represent potential tyrosine phosphorylation
sites and potential interactors with SH2 domain-containing
phosphatases [16].
The aim of this study was to determine the potential role of
SHP-2 in CCK2 receptor signalling, and in particular to analyze
the molecular mechanisms involved.2. Materials and methods
2.1. Antibodies and materials
Immunoprecipitation and western blot assays were performed using the
following antibodies : anti-SHP-2 (BD Biosciences, Le Pont de Claix, France),
anti-pY580 SHP-2, anti-pS473 AKT, anti-phospho-ERK1/2 (Cell Signaling
Technology, Danvers, MA, USA ), anti-HA tag clone 16B12 (Covance Research
Products, Denver, PA, USA), anti-AKT, anti-ERK2 (Santa Cruz, Heidelberg,
Germany). Calpeptin was purchased from Calbiochem (EMBD Bioscience Inc.,
San Diego, CA, USA) and Streptavidin sepharose from GE Healthcareof the CCK2 receptor amino acid sequence with ITIM-like motifs (in black) and
of C-terminus sequences of the CCK2 receptor in different species.
Fig. 2. Pull-down assays. Biotinylated ITIM peptides containing the tyrosine
438, phosphorylated or not (pY438 or Y438), coupled to streptavidin sepharose
were used to precipitate SHP-2 from lysates of different cell lines, expressing
(AR4-2J) or not (COS-7, NIH3T3) the endogenous CCK2R. Precipitated
proteins were separated by SDS-PAGE then blotted with an anti-SHP-2
antibody.
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zenyl-quinoline-5-sulfonic acid) was purchased from Fisher Bioblock Scientific
(Illkirch, France). The following peptides were synthetized as previously
described [17] and used for pull-down and SPR assays:
ITIM-Y390: biotin SYASASVNPLVYCFMHRR-NH2
ITIM-pY390: biotin-SYASASVNPLVY(PO3)CFMHRR-NH2
ITIM-Y438: biotin-SIASLSRLSYTTISTLGPG-NH2
ITIM-pY438: biotin-SIASLSRLSY(PO3)TTISTLGPG-NH2
2.2. Cell culture and transfection
COS-7, NIH3T3 and AR4-2J cells were grown in DMEM supplemented
with 5% (COS-7 and NIH3T3) or 10% (AR4-2J) foetal calf serum at 37 °C
under a 5% CO2 controlled atmosphere.
Mutant CCK2R, Y438F-CCK2R was previously described [17]. Plasmids
coding for wild type or mutant CCK2R were transiently transfected into COS-7
cells with Jet-PEI (Polyplus Transfection) according to the manufacturer's
conditions.
Cells are serum-starved 18 h prior gastrin stimulation. When indicated, cells
were treated for 1 h prior stimulation with calpeptin or vehicle as previously
described [18].
2.3. Pull-down assays
Biotinylated peptides (10 μg) corresponding to the different CCK2 receptor
ITIM-like sequences were coupled for 1 h to streptavidin sepharose at room
temperature, then incubated for 2 h with cell lysates (1 mg of proteins per assay)
at 4 °C. Beads were washed tree times with 20 mMNaH2PO4, 150 mMNaCl pH
7.5. Proteins were then separated by SDS-PAGE and analyzed by western blot as
described previously [10].
2.4. Western blot analysis
Western blot analyses were performed on cell lysates or immunoprecipitates
from AR4-2J or COS-7 cells stimulated or not with gastrin. Fractions containing
identical amount of proteins, were separated by SDS-PAGE and analyzed by
western blot with the indicated antibodies as described previously [10].
2.5. Surface plasmon resonance assays
All binding and kinetics studies based on SPR technology were performed
on a four-channel BIAcore 3000 optical biosensor instrument (BIAcore AB,
Uppsala, Sweden). Immobilization of biotinylated peptides was performed on a
streptavidin-coated sensorchip (BIAcore SA sensorchip) in HBS-EP buffer
(10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20)
(BIAcore AB, Uppsala, Sweden).
All immobilization steps were performed at a final peptide concentration of
100 ng/ml at a flow rate of 10 μl/min. Injections were stopped when sufficient
RU levels were obtained. Levels of immobilized peptides were: for ITIM-Y438,
100 RU on flow cell 1; for ITIM-pY438, 96 RU on flow cell 2; for ITIM-Y390,
100 RU on flow cell 3 and for ITIM-pY390 106 RU on flow cell 4.
Binding analyses were performed with different concentrations of purified
recombinant proteins (GST-SHP-2, GST-SH2-SHP-2 and GST-SHP-1) injected
over the immobilized peptides surface at 25 °C for 4 min at a flow rate of 30 μl/
min in a K-Inject mode. All diluted samples were injected at the same time over
the four channels (flow cells).
Kinetics constants (ka and kd) were calculated using BIAevaluation 4.0.1
software. Apparent equilibrium dissociation constants (KD) were calculated as
the ratio of kd/ka.
2.6. Statistical analysis
Quantification of western blot results were performed with Phoretix 1D
software and data analyzed for means, ±SEM and Student t tests with Graphpad
prism software. (***p<0.001; **0.001<p<0.01; *0.01<p<0.5; ns p>0.5).3. Results
3.1. Interaction of phosphorylated tyrosine 438 of the CCK2
receptor with the phosphatase SHP-2
We tested the hypothesis that an interaction existed between
the phosphorylated ITIM-like motifs of the CCK2R and the
SH2 domains of SHP-2.
We first performed pull down assays with biotinylated
synthetic peptides corresponding to the CCK2R ITIM-like
sequences, phosphorylated or not on the tyrosine residues. For
this purpose we used lysates from different cell lines expressing
(AR42J) or not (COS-7, NIH3T3) the endogenous CCK2R.
Using a specific anti-SHP-2 antibody, we were able to co-
precipitate the phosphatase with the ITIM-like peptide of the
CCK2R containing the phosphorylated tyrosine 438 (pY438).
However, the non-tyrosyl-phosphorylated peptide Y438 (Fig. 2)
or the ITIM-like motifs Y390 and pY390 (data not shown)
showed either no interaction or a weak one.
To test if a direct interaction existed between the phosphory-
lated ITIM-like motifs of the CCK2R and SHP-2, we used the
surface plasmonic resonance technique (SPR, BIAcore 3000).
Synthetic tyrosyl-phosphorylated (pY390, pY438) or non-
tyrosyl-phosphorylated peptides (Y390, Y438), corresponding
to the different CCK2R ITIM-like sequences, were coated on the
BIAcore sensor chip. Fig. 3A shows that the purified GST-SHP-
2 recombinant protein, used as an analyte, interacts with the
immobilized phosphorylated ITIM-like peptide containing the
tyrosine 438 (pY438) of the CCK2R. No or only a weak
interaction was detected with the tyrosyl-phosphorylated
peptide, pY390 (Fig. 3B). Binding of recombinant SHP-2 to
phosphorylated ITIM-like peptide pY438 was dose-dependent
(3–100 nM) (Fig. 3A), allowing us to determine the affinity
between the phosphatase and this phosphorylated sequence
(kd=2.3 nM). In contrast no significant interaction was observed
between this CCK2R motif and SHP-1, another member of the
SH2 domains-containing non-receptor tyrosine phosphatase
family, showing the specificity of the interaction between the
CCK2R and SHP-2 (Fig. 3C).
The GST-SH2-SHP-2 recombinant protein, corresponding to
the two SH2 domains of SHP-2, but lacking the phosphatase
domain was still able to bind to the phosphorylated ITIM
peptide pY438 (kd=42.3 nM) (Fig. 3D). As expected, we did
not observe any interaction between the phosphorylated ITIM
peptide pY390 and the GST-SH2-SHP2 (Fig. 3E).
Fig. 3. Surface plasmon analysis of SHP-2 binding to CCK2R ITIM-like peptides. (A) Dose-dependant binding of the full length recombinant SHP-2 (GST-SHP-2) to
the ITIM-(p)Y438 peptide. (B) Comparison of the binding between GST-SHP-2 and the two phosphorylated ITIM-peptides, ITIM(p)Y438 and ITIM(p)Y390. (C)
Comparison of the binding between the full length recombinant SHP-1 (GST-SHP-1) or GST-SHP-2 to the ITIM-(p)Y438 peptide. (D) Dose-dependent binding of
GST–SH2–SHP-2 recombinant protein, corresponding to the two SH2 domains of SHP-2, to the ITIM-(p)Y438 peptide. (E) Comparison of the binding between
GST–SH2–SHP-2 and the two phosphorylated ITIM-peptides, ITIM(p)Y438 and ITIM(p)Y390. All sensorgrams are expressed in resonance units (RU) of binding
ratio between phosphorylated/non-phosphorylated peptides.
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ITIM sequence and SHP-2 also exists in cells, we used COS-7
cells transiently transfected with a HA-tagged wild type
CCK2R (WT HA-CCK2R). Immunoprecipitation with an
anti-HA antibody and western blotting with an anti-SHP-2
antibody showed a time-dependent increase in the amount ofSHP-2 protein co-precipitated with the receptor in response to
gastrin. This increase in CCK2R/SHP-2 binding after gastrin
treatment was not observed when the tyrosine 438 is mutated
into phenylalanine (HA-CCK2R Y438F) (Fig. 4).
The pharmacological characteristics of HA-CCK2R Y438F
were previously analyzed by ligand binding experiments which
Fig. 4. Recruitment of SHP-2 to the CCK2 receptor requires the tyrosine 438. COS-7 cells transiently transfected with HA-tagged wild type CCK2R (WT HA-
CCK2R) or HA-tagged CCK2R mutated on tyrosine 438 into phenylalanine (HA-CCK2R-Y438F) were stimulated by gastrin (10 nM) for the time indicated. Cell
lysates were immunoprecipitated with anti-HA antibody. Immunoprecipitated proteins were loaded on SDS-PAGE and blotted with anti-SHP-2 antibodies. Blots were
also re-probed with antibodies directed against HA-tag. Densitometric analyses of data are presented as means±SE of three independent experiments.
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maximal binding capacity similar that of WT HA-CCK2R [17],
indicating that the mutation of Y438 into phenylalanine neither
affects the high affinity binding of CCK2R agonists nor the cell
surface receptor expression.
3.2. Tyrosine 438 of the CCK2R and SHP-2 are involved in
AKT activation by gastrin in COS-7 cells
Numerous publications have reported that SHP-2 can
function as a positive regulator in growth-stimulatory signalling
pathways (for review [1,2]). In particular, SHP-2 is known to
play a positive role in the activation of the ERK cascade, or in
signalling pathways involving AKT, or the signal transducers
and activators of transcription (STATs).
The activation of AKT was analyzed by immunoblotting
with antibodies which specifically recognize the phosphory-
lated and therefore activated form of AKT. As shown in Fig. 5A,
COS-7 cells transfected with the wild type CCK2R show
gastrin-stimulated AKT activation within 15 min of gastrin
treatment. This stimulation is maintained at 30 and 60 min. In
contrast, cells transfected with the mutant CCK2R Y438F
display no activation of AKT in response to gastrin, indicating
the necessity of tyrosine 438. Western blot analysis for total
AKT expression revealed an equal amount of protein in
transfected cells.
Furthermore, pretreatment of CCK2R expressing COS-7
cells with SHP-2 specific phosphatase inhibitors, calpeptin [18]
or NSC-87877 [19] totally blocks gastrin-induced AKT
phosphorylation, indicating that SHP-2 phosphatase activity isrequired for the activation of the AKT pathway by the CCK2R
in these cells (Fig. 6).
In order to analyze the role of tyrosine 438 in the activation
of the ERK cascade by the CCK2R, we immunoblotted with
anti-phospho-ERK1/2 antibody. We found that activation of this
signaling pathway by gastrin is not affected by the Y438F-
CCK2R mutant (Fig. 5B).
Western blot analysis for ERK2 protein expression revealed
an equal amount of the protein in transfected cells.
3.3. CCK2R induces the phosphorylation of SHP-2 on tyrosine
580 in COS-7 cells
SHP-2 has been shown to undergo phosphorylation on
tyrosine residues within the C-terminal tail. In addition to a
possible adapter role for SH2 containing proteins, tyrosine
phosphorylation of SHP-2 may contribute directly to the positive
regulation of its phosphatase activity [3]. In response to gastrinwe
observe an increase in the phosphorylation of SHP-2 on tyrosine
580 which is blocked by the mutation Y438F (Fig. 7). The kinetic
of SHP-2 phosphorylation, maximal at 3 min, correlates with the
rapid recruitment of the phosphatase by the CCK2R (Fig. 4).
Western blot analysis for SHP-2 protein expression revealed an
equal amount of the protein in transfected cells.
3.4. Role of SHP-2 in the activation of the AKT pathway by the
endogenous CCK2R in pancreatic tumour cells
We used the AR4-2J cells to analyze the role of SHP-2 in
the activation of the AKT pathway by an endogenous
Fig. 5. Role of tyrosine 438 in AKTor ERK1/2 activation by the CCK2R. COS-7 cells transiently transfected with HA-tagged wild type CCK2R (WT HA-CCK2R) or
HA-tagged CCK2R mutated on tyrosine 438 into phenylalanine (HA-CCK2R-Y438F) were stimulated by gastrin (10 nM) for the time indicated. Equal amount of cell
lysates proteins were loaded on SDS-PAGE and analyzed by western blot. (A) Membranes were probed with an anti-phospho-Ser473 AKT antibody and re-probed
with an anti-AKT antibody as control. (B) Membranes were probed with an anti-phospho-ERK1/2 antibody and re-probed with an ERK2 antibody as loading control.
Equal amount of cell lysates proteins were also analyzed by western blot with antibodies directed against HA-tag to ensure equal transfection (not shown).
Densitometric analyses of data are presented as means±SE of three independent experiments.
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transiently transfected with the CCK2R, we detected an
increase in the phosphorylation of SHP-2 on tyrosine 580 in
response to an activation of the endogenous receptor by
gastrin (Fig. 8A).
In this model, we also confirmed that the CCK2R was able
to induce AKT activation. Using an anti-phospho-AKT
antibody we detected a significant increase in AKT activation
15 min after stimulation of the CCK2R by gastrin. The time
course of phosphorylation was similar to that observed in
COS-7 cells (Fig. 8B). Pretreatment of the AR4-2J cells withthe SHP-2 specific phosphatase inhibitor, calpeptin [18],
results in total inhibition of gastrin-induced AKT phosphor-
ylation (Fig. 8C). This indicates that SHP-2 phosphatase
activity is required for the activation of the PI3-kinase/AKT
pathway by the CCK2R in cells that express the endogenous
receptor.
4. Discussion
In addition to the negative regulation of RTKs, some
phosphatases such as SHP-2 have been shown to function in a
Fig. 6. Role of SHP-2 in AKTactivation by the CCK2R in COS-7 cells. COS-7 cells transiently transfected with HA-tagged wild type CCK2R (WTHA-CCK2R) were
incubated with SHP-2 inhibitors, (A) calpeptin (100 μg/mL for 1 h) or (B) NSC-87877 (50 μM for 3 h) or vehicle prior to gastrin stimulation (10 nM). Equal amount of
cell lysates proteins were loaded on SDS-PAGE and analyzed by western blot using an anti-phospho-Ser473 AKT antibody or an anti-AKT antibody as indicated.
Equal amount of cell lysates proteins were also analyzed by western blot with antibodies directed against HA-tag to ensure equal transfection (not shown).
Densitometric analyses of data are presented as means±SE of three independent experiments.
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factor receptors. In particular, SHP-2 has been shown to be
essential for mediating mitogenic and anti-apoptotic signals
induced by RTKs. In most cases, SHP-2 is recruited through its
SH2 domains by phosphorylated tyrosine residues present on
RTKs or adapter proteins [1,2]. In the present study, we show
that the activation of the CCK2 receptor, a GPCR, also resultsin SHP-2 recruitment and the subsequent activation of the
AKT pathway which is known to be involved in the anti-
apoptotic effects of this receptor. We have identified a highly
conserved ITIM-like sequence, located in the C-terminal
intracellular tail of the CCK2R, which is involved in the
interaction between the tyrosine phosphatase SHP-2 and the
receptor. This type of sequence phosphorylated on the key
Fig. 7. Tyrosine phosphorylation of SHP-2 following CCK2R activation. COS-7 cells transiently transfected with HA-tagged wild type CCK2R (WT HA-
CCK2R) or HA-tagged CCK2R mutated on tyrosine 438 into phenylalanine (HA-CCK2R-Y438F) were stimulated by gastrin (10 nM) for the time indicated.
Equal amount of cell lysates proteins were loaded on SDS-PAGE and analyzed by western blot. Membranes were probed with anti-phospho-Y580 SHP-2
antibodies and re-probed with an anti-SHP-2 antibody as control. Equal amount of cell lysates proteins were also analyzed by western blot with antibodies
directed against HA-tag to ensure equal transfection (not shown). Densitometric analyses of data are presented as means±SE of three independent
experiments.
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directly interact with SH2 domain-containing phosphatases
[16]. Using surface plasmon resonance, we showed that the
CCK2R ITIM motif, containing the phosphorylated tyrosine
residue 438 binds directly to the SHP-2 SH2 domains whereas
the non-tyrosyl-phosphorylated peptide shows no interaction.
The KD values, 42.3 nM for the SHP-2 SH2 domains and 2.3
nM for the whole protein were comparable to those reported for
the bradykinin B2 receptor [8] or the platelet endothelial cell
adhesion molecule-1 [20]. Sweeney et al. have reported KD
values in the micromolar range (between 0.1 and 10 μM) for
phosphotyrosyl peptides toward SHP-2 SH2 domains [4].
However, in this study, they used minimal recognition motifs
that include only three amino acids in position +1 to +3 relative
to pY. More recently the same group demonstrated the
important contribution of the amino acids at pY+4 to pY+6
positions to the binding affinity [5]. In our study the use of long
phosphotyrosyl peptides (19 amino acids, pY-9 to pY+9) and
the whole SHP-2 protein might explain the high affinities
observed.
We did not observe any interaction between the CCK2R
ITIM motif and SHP-1, another SH2 domain-containing
phosphatase which presents a high homology with SHP-2.
The selectivity of the interaction toward the SH2 domains of
SHP-2 suggests a potential role of the amino-acids adjacent to
the ITIM motif in the recognition of the phosphatase by the
CCK2R. Such specificity toward SHP-1 or SHP-2 has been
previously reported for other receptors containing ITIM
sequences [21,22].
We also confirmed the interaction between SHP-2 and the
CCK2R in COS-7 cells transfected with the receptor by
mutational analysis of the key ITIM residue, Tyrosine 438.We showed a time-dependent increase in the amount of SHP-2
co-precipitated with the CCK2R in response to gastrin that is
not observed when the tyrosine 438 is mutated into phenyla-
lanine. Although the results obtained with the BIAcore
technology in vitro show the involvement of the phosphoryla-
tion of the ITIM motif, we cannot exclude that in COS-7 cells,
tyrosine 438 itself, rather than its phosphorylation is important
in SHP-2 binding.
Mutation of tyrosine 438 within the CCK2R sequence also
abolished the activation of the AKT pathway induced by
CCK2R stimulation, suggesting that SHP-2 might act upstream
of AKT.
The inhibition of CCK2R-induced AKT activation with
SHP-2 inhibitors confirmed this hypothesis in the different cell
models used in this study. In contrast, in CCK2R signalling,
SHP-2 does not seem to be involved in the ERK1/2 cascade
since the activation of this pathway by gastrin is not modified
with the Y438F-CCK2R mutant. In addition as we mentioned in
a previous report, mutation of tyrosine 438 within the CCK2R
sequence does not affect the activation of JAK2 by gastrin
suggesting that SHP-2 is not involved upstream the JAK2/
STAT3 pathway which is known to be activated by this receptor
[10]. In contrast, the Angiotensin receptor, AT1, which also
belongs to the GPCR family and mediate proliferative effects,
has been shown to activate the ERK1/2 pathway and JAK2 via
SHP-2. In this study, the authors suggest the involvement of a
YIPP motif in the AT1 receptor sequence in the interaction with
SHP-2 [6].
Similar to the observations made by others with RTKs [3] but
also the AT1 receptor [23], we observed the tyrosine
phosphorylation of SHP-2 on Tyrosine 580. This phosphory-
lated tyrosine residue has been previously shown to play a role
Fig. 8. Role of SHP-2 in AKT activation by the CCK2R in a pancreatic tumour cell line. AR4-2J cells were stimulated with gastrin (10 nM) for the time indicated.
When indicated in panel C AR4-2J cells were incubated with calpeptin (100 μg/mL) or vehicle for 1 h prior stimulation. Equal amount of cell lysates proteins were
loaded on SDS-PAGE and analyzed by western blot. (A) Membranes were probed using an anti-phospho-Y580 SHP-2 antibody and re-probed with an anti-SHP-2
antibody as control (B and C) Membranes were probed using an anti-phospho-Ser473 AKT antibody and re-probed with an anti-AKT antibody as control. Results of
autoradiography quantification are presented as means±SE of three independent experiments.
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Grb2 through its SH2 domain and leading to ERK pathway
activation. We did not observe any interaction between SHP-2
and the adapter protein Grb2 following CCK2R activation (data
not shown). However we hypothesize that SHP-2 might interact
with other SH2 domain-containing signalling molecules
involved in AKT pathway that remain to be identified. Besides
a possible adapter role, tyrosine phosphorylation of SHP-2
might regulate the phosphatase activity [3].
In summary, the present study demonstrates the role of SHP-
2 in the activation of the AKT pathway by the CCK2R and the
requirement of an ITIM-like motif within the CCK2 receptorsequence for the interaction with SHP-2 and the activation of
the AKT pathway.
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